What Пинеамин (Pineamin) Treats: Main Uses and Benefits

Пинеамин (Pineamin) is used in therapeutic domains involving the management of neurovisceral symptoms associated with climacteric conditions. Its use is considered relevant in clinical contexts that involve acute or unstable symptom patterns, as well as those involving fluctuating manifestations.

The medication is used to provide symptomatic relief for women experiencing neurovegetative disorders, helping to address distressing physical symptoms and related psychoemotional manifestations. It is applied to ease the burden of symptoms that include episodic hot flashes, excessive sweating, heart palpitations, irritability, mood swings, and sleep disturbances like menopausal insomnia.

The medication is considered relevant for symptomatic support in patients who are unable to use, or choose to avoid, traditional Hormone Replacement Therapy (HRT). It is commonly applied in scenarios where additional management of discomfort is required, offering supportive relief when symptoms interfere with routine activities.

“This treatment supports the patient during difficult episodes by easing distress and contributing to easing the overall symptom load.”

---

Quick Fact: Relief for Climacteric Discomfort

Пинеамин is applied across domains where symptomatic support is needed, assisting with maintaining a sense of stability and contributing to improved comfort during periods of heightened symptoms associated with the menopausal transition.

Regulatory References

1. News on inclusion in Ministry of Health guidelines

Who Can and Cannot Use Пинеамин (Pineamin)

The eligibility profile for Пинеамин is strictly defined by regulatory authorities and centers on adult women with specific gynecological indications, while explicitly prohibiting use in several key populations.

Populations Allowed and Contraindicated

Eligibility Status	Specific Population Rule
Allowed	Adult women (age 18+) for neurovisceral disorders associated with menopausal syndrome.
Contraindicated	Individuals under age 18 (pediatric population).
Contraindicated	Pregnant or breastfeeding individuals.

---

Condition-Based Eligibility Rules

Use is absolutely prohibited (contraindicated) for patients diagnosed with pre-cancer and malignant diseases, including estrogen-dependent tumors of reproductive organs or breasts, and in cases of metrorrhagia (vaginal bleeding of unclear origin).

Conditional use is required for certain benign conditions: the medicine must be used with caution in women with uterine leiomyoma or endometriosis. Additionally, due to potential hypersensitivity, a trial injection is officially recommended before starting full therapy.

This structure ensures the medicine is reserved for the officially designated adult female population and avoids use in contexts where specific gynecological or reproductive risks are present, as defined by official labeling.

The interaction profile for Пинеамин (Pineamin) is formally characterized by the absence of specific, documented findings concerning co-administration with other medicinal products, foods, or supplements, based on its official government-approved prescribing information. The regulatory documentation for this medicine does not currently include dedicated studies on drug-drug interactions, nor does it detail specific known mechanisms involving metabolic pathways or drug transporters.

Interaction Category	Official Regulatory Status
Documented Drug-Drug Interactions	None documented.
Metabolic/Enzyme Interactions	None documented.
Contraindicated Combinations	None documented.
Timing/Separation Requirements	None documented.
Food, Alcohol, Herbal Products	None documented.

The official regulatory label does not list any specific medicinal products that are formally contraindicated for use with Пинеамин. There are no designated substances that are officially documented to alter the exposure (such as the plasma concentration or clearance) of Пинеамин through enzyme inhibition or induction. Furthermore, the official documents do not impose any mandatory rules regarding the separation of doses in time when Пинеамин is administered alongside other drugs. No specific warnings or restrictions are documented concerning interactions with food, alcohol, or herbal products in the product’s official interaction section. The regulatory structure is defined by the current lack of specific, documented interaction data across all standard regulatory categories, indicating no formally identified risks of interaction according to the governing authority.

How Pineamin (Пинеамин) Works

Pineamin, a complex peptide preparation derived from the pineal gland, exerts its effect through the modulation of central neuroendocrine processes. Its primary action involves targeted interaction within the hypothalamic-pituitary-adrenal (HPA) axis and associated feedback loops. The drug's peptides selectively engage mechanisms that influence the synthesis, release, and receptor sensitivity of various signaling molecules, particularly within the monoaminergic system, including serotonin and dopamine.

This molecular interaction modifies early intracellular steps that govern systemic physiological regulation. By adjusting neuroendocrine output, Pineamin supports the regulation of pathways prone to dysregulation. Downstream consequences involve the modulation of circadian and endocrine cycles, alongside an influence on cellular processes related to oxidative stress and metabolic dynamics, affecting the overall functionality of targeted neural tissues.

The official administration protocol for Пинеамин (Pineamin) defines its use through a standardized, short-term, cyclical parenteral regimen based on national regulatory documentation. The product is formulated as a lyophilisate for the preparation of a solution, and the sole approved method of delivery is by intramuscular (IM) injection.

Standard Administration and Dosing

The medicine is administered as a single daily dose of 10 mg, corresponding to the contents of one vial. This dose is given once daily over a limited course duration. The standard treatment pattern consists of 10 consecutive days. If the regimen is to be repeated, regulatory guidance specifies a mandatory interval of 3 to 6 months must elapse between courses.

Preparation and Handling

Due to the nature of the formulation, the lyophilisate must be dissolved immediately prior to use. This reconstitution requires 1-2 mL of one of the officially recognized diluents: 0.9% sodium chloride solution, water for injections, or 0.5% procaine solution. The resulting solution cannot be stored and must not be mixed with any other injectable solutions.

Special Usage Guidelines	Labeled Instruction
Missed Dose	A double dose must not be administered; the regimen should continue with the next scheduled injection.
Renal Impairment	No dose adjustment is required for patients with renal impairment.
Route Restriction	Administration via the subcutaneous (SC) or intravenous (IV) route is explicitly prohibited.

The entirety of the administration procedure—from dilution to dose frequency—is governed by these official protocols, structuring the medicine's application into a defined, non-adjustable therapeutic cycle.

Research Evidence / Overview of Studies for Пинеамин (Pineamin)

Evidence for Neurovisceral Symptoms of Climacteric Syndrome

Research was studied for its use in conditions characterized by fluctuating or episodic manifestations associated with the climacteric (menopausal) syndrome. Research includes multicenter, double-blind, placebo-controlled Randomized Controlled Trials (RCTs). These study designs are relevant in trials assessing short-term or episodic symptom patterns and are used in research exploring how symptoms change over time. These studies examined patient-reported experiences related to physical discomfort and psycho-emotional distress in postmenopausal women (typically 45 to 60 years).

The findings describe patterns observed in these studies, focusing on changes measured in symptoms over the study period. The evidence is derived from settings with varying symptom burdens, and these findings contribute to the broader evidence landscape.

Exploratory Research and Evidence Gaps

Research explored its use in specific contexts, with studies focusing on outcomes related to systemic or functional imbalance. Specifically, small-scale comparative studies have research examined the levels of 6-sulfatoxymelatonin (6-SOMT), a metabolic marker that reflects pineal gland function, in elderly patients (e.g., ages 60–74).

Other research included pilot multicenter, randomized, comparative studies for men diagnosed with pathozoospermia and associated male aging symptoms. These studies monitored changes in sperm parameters and patient-reported discomfort over short-term intervals of approximately three months.

The certainty remains low regarding the clinical implications of these exploratory studies. Long-term effects are not fully established for any indication, as the follow-up durations were limited and the sample sizes were modest across much of the supporting research. Data for certain groups, such as patients with complex pre-existing conditions, also remain insufficient.

Key Studies & References Pineamin® Product Information (Russian Federation Regulatory Data)

Common questions about Пинеамин (Pineamin) (FAQ)

Q: What is the general purpose of Пинеамин (Pineamin) according to official information?

Official regulatory documents classify this product as an anti-menopausal medicine. According to this information, the primary indication is for treating neurovisceral disorders, which include physical and psychological symptoms associated with menopausal syndrome.

Q: What is the difference between Пинеамин (Pineamin) and other peptide bioregulators?

Official descriptions define this product as a complex of polypeptides specifically derived from the bovine pineal gland. Its mechanism involves targeted interaction within the central neuroendocrine system, which separates it from other peptide complexes that may be derived from different sources.

Q: How long do the effects of Пинеамин (Pineamin) last after a full course?

Official administration protocols guide the spacing of treatment cycles. Regulatory instructions state that a period of 3 to 6 months must elapse between treatment courses if the regimen is repeated. The official documentation does not specify the exact duration of the effects, but regulatory instructions mandate this interval for safety before repeating the cycle.

Q: Is there clinical research confirming the uses of Пинеамин (Pineamin)?

Official product information references clinical studies, including controlled randomized trials (RCTs), that examined its use for neurovisceral symptoms related to menopausal syndrome.

Q: Is it true that Пинеамин (Pineamin) is used for mental wellness support?

The official prescribing information notes that the medicine is used to address specific psycho-emotional symptoms of menopausal syndrome. This includes manifestations such as depression and irritability, as the product is described as modulating neuroendocrine processes.

Q: Does Пинеамин (Pineamin) have an effect on sleep patterns?

Official documentation includes insomnia (difficulty sleeping) among the menopausal symptoms for which the medicine is prescribed. Furthermore, the product is described as influencing circadian cycles and the synthesis of endogenous melatonin, a hormone involved in regulating sleep.

Q: What should I do if I miss a scheduled application of Пинеамин (Pineamin)?

The regulatory instructions clearly state that a double dose must not be administered. The regimen is structured to continue with the next scheduled injection as originally planned.

Q: What kind of doctor typically prescribes or recommends Пинеамин (Pineamin)?

As the medicine's primary indication is for disorders associated with menopausal syndrome in women, it is typically prescribed by specialists in the field of gynecology. Any prescribing decision should align with your country’s specific regulatory guidance.

Q: Is Пинеамин (Pineamin) a prescription drug or over the counter?

The product is regulated as a medicinal product and is governed by official administration protocols and prescribing information. This level of regulatory control indicates that it is typically not available over the counter.

Q: Does Пинеамин (Pineamin) cause tiredness or sleepiness?

The official regulatory documentation for this medicine does not list tiredness or sleepiness as documented adverse reactions or side effects.

Q: Are there any long-term effects associated with using Пинеамин (Pineamin)?

Official research documentation states that long-term effects are not fully established due to the limited follow-up duration of clinical studies. However, pre-clinical studies lasting up to 90 days did not show negative effects on major body systems.

Q: Can people with high blood pressure use Пинеамин (Pineamin)?

High blood pressure (hypertension) is not included in the official list of contraindications for this medicine. Its use is restricted only by the specific conditions listed in the product’s prescribing information.

Q: Can individuals with kidney or liver conditions use Пинеамин (Pineamin)?

Official guidance states that no dose adjustment is necessary for patients who have renal impairment (kidney issues). Furthermore, the product is officially described as having no negative effect on liver function.

Q: Can Пинеамин (Pineamin) be used by people with autoimmune conditions?

Autoimmune conditions are not listed in the official documentation as a contraindication or an explicit warning for this medicine. Contraindications are limited to the specific conditions detailed in the prescribing information.

Q: Is there information on whether Пинеамин (Pineamin) affects fertility?

While the medicine is contraindicated during pregnancy and breastfeeding, research has explored its use in men diagnosed with pathozoospermia, a condition related to sperm parameters and male reproductive function.

Q: Does the official documentation specify any contraindications related to cancer history?

The medicine is absolutely prohibited (contraindicated) for patients with current pre-cancer and malignant diseases, including estrogen-dependent tumors. The official documentation does not separately detail the specific use case of a past history of cancer.

Q: Can the effectiveness of Пинеамин (Pineamin) be reduced by certain foods or drinks?

Official regulatory documentation does not include any information or warnings indicating that the effectiveness of the medicine may be reduced by specific foods or drinks. The interaction profile is characterized by a lack of documented findings.

Q: Is the packaging for Пинеамин (Pineamin) designed to protect it from light or heat?

Official storage requirements mandate that the product must be stored protected from light and within a specific temperature range (2–20 °C). The packaging is designed to maintain these stability requirements, supporting the safety and quality control of the medicine.

Q: Does official labeling mention any restrictions on driving or operating machinery while using Пинеамин (Pineamin)?

Official regulatory documentation does not list any specific restrictions or warnings regarding the ability to drive or operate machinery while using the medicine.

Q: Does official information state whether Пинеамин (Pineamin) affects mood directly?

Official information describes the drug's mechanism as involving the monoaminergic system, which regulates mood-related signaling molecules. It is noted for its use in treating psycho-emotional symptoms of menopausal syndrome, such as depression and irritability.

Q: What is the difference in composition between Пинеамин (Pineamin) and Epithalamin?

Both products are described as being derived from the pineal gland polypeptide complex. Pineamin is officially described as a complex of water-soluble polypeptide fractions, and studies have noted that both exhibit a similar effect on the synthesis of melatonin.

Q: Do regulatory agencies classify Пинеамин (Pineamin) as a hormone replacement?

Regulatory agencies classify the product as an anti-menopausal medicine with a Polypeptides of Pineal Gland (PPG) class effect. Its mechanism is described as acting through the regulation of central neuroendocrine processes rather than direct hormone replacement.

Official Storage and Disposal Requirements

Official regulatory documents define specific conditions for storing and disposing of Пинеамин (Pineamin) to ensure product stability and safety. The medication is required to be stored within a controlled temperature range and protected from light.

Storage Component	Official Requirement
Temperature	Store protected from light at 2–20 °C (36–68 °F)
Light Protection	Store protected from light
Stability	Do not keep and use the drug solution after the expiry date
Handling	Keep the product protected from light

The regulatory labeling dictates that once the solution is prepared, it must not be used past the expiration date printed on the vial. Regarding disposal, the official documentation states that special precautions when destroying unused drug are not needed.